Stocks · News reference

bioAffinity Technologies to Present CyPath Lung Test at North Carolina Healthcare Event

2026-10-30 13:05:05 UTC

bioAffinity Technologies announced it will participate in the Lung Cancer Initiative of North Carolina's "Battle of the Blues" event on November 5, 2026, to discuss its CyPath Lung diagnostic test.

More stocks news Connected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BIAF

Source: fiscal.ai
Observed: 2026-10-30 13:05:05 UTC
Checked: 2026-10-30 13:06:20 UTC
Cadence: Captured once, then retained as an archive reference
Status: fresh

Keep reading

Benzinga2026-10-13 12:02:54 UTCBenzinga Newsdesk
bioAffinity Technologies To Present New Data On Sputum-Based Tests In Development To Characterize Lung Inflammation And Detect Multiple Protein Biomarkers Of Lung Inflammation At CHEST 2026
Findings report on ability to measure cellular and soluble inflammatory protein biomarkers in sputum, including biologic drug targetsCompany advances research and development in diagnostic tests for major lung diseases
BIAF
Benzinga2026-10-08 16:49:29 UTCBenzinga Newsdesk
BIAF stock has given up its prior gain. bioAffinity Technologies shares were trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.
BIAF
Benzinga2026-10-08 16:10:36 UTCBenzinga Newsdesk
bioAffinity Technologies Commences ~$4M Offering Of Common Stock At $6.122 Per Share
BIAF
Benzinga2026-10-08 16:02:53 UTCBenzinga Newsdesk
bioAffinity Technologies shares are trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.
BIAF
Benzinga2026-10-08 12:02:59 UTCBenzinga Newsdesk
bioAffinity Technologies Says Japan Patent Office Intends To Grant Patent For CyPath Lung Cancer Test
BIAF
Benzinga2026-10-06 13:23:28 UTCBenzinga Newsdesk
bioAffinity Technologies Announces 100% Increase In Sales For Its CyPath Lung Test For Lung Cancer
BIAF

bioAffinity Technologies to Present CyPath Lung Test at North Carolina Healthcare Event

Connected Markets

Related Headlines

bioAffinity Technologies To Present New Data On Sputum-Based Tests In Development To Characterize Lung Inflammation And Detect Multiple Protein Biomarkers Of Lung Inflammation At CHEST 2026

bioAffinity Technologies Commences ~$4M Offering Of Common Stock At $6.122 Per Share

bioAffinity Technologies shares are trading higher after the company announced that the Japan Patent Office issued a Notice of Allowance indicating its intention to grant a patent for the method of predicting the likelihood of lung cancer powered by the CyPath Lung test for early-stage lung cancer.

bioAffinity Technologies Says Japan Patent Office Intends To Grant Patent For CyPath Lung Cancer Test

bioAffinity Technologies Announces 100% Increase In Sales For Its CyPath Lung Test For Lung Cancer